Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015121 | 0.85 | KMO (0.58) | KMOPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1013024 | 0.82 | KMO (0.52) | KMOFFAR4PDE4BACACBPDE4A | |
| SCHEMBL4257689 | 0.81 | KMT2A (0.55) | THRATHRB | |
| SCHEMBL2090182 | 0.81 | KMO (0.46) | KMOPDE4BACACBPDE4APDE4C | |
| SCHEMBL8354077 | 0.80 | THRA (0.43) | THRATHRB | |
| SCHEMBL18910042 | 0.80 | FFAR4 (0.58) | KMOFFAR4THRATHRBP2RX3 | |
| SCHEMBL663986 | 0.80 | MAP4K4 (0.54) | KMO | |
| SCHEMBL1391337 | 0.78 | KMO (0.49) | KMOPDE4BACACBPDE4APDE4C | |
| SCHEMBL2088066 | 0.77 | PARP15 (0.62) | PDE4B | |
| SCHEMBL9263449 | 0.77 | ALDH1A1 (0.57) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645772-B2 | 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-01-12 | — | — | US | claimed |
| US-20060035970-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2006-02-16 | — | — | US | claimed |
| EP-1556085-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| US-7645772-B2 | 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060035970-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2006-02-16 | — | — | US | disclosed |
| EP-1556085-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041165-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |